Skip to main content
. 2019 May 10;110(1-2):83–91. doi: 10.1159/000500862

Fig. 1.

Fig. 1

Progression-free survival among 138 patients with advanced pancreatic neuroendocrine tumors treated with temozolomide (TEM) or TEM-capecitabine (TEM-CAP). a Raw analysis. b Analysis of patients matched for their propensity score. c Analysis using the inverse probability treatment weighting method.